Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer
In patients with metastatic bladder cancer, a novel combination of biomarkers from baseline tumor tissues was predictive of improved clinical responses and prolonged survival following treatment with immune checkpoint inhibitors, according to researchers from The University of Texas MD Anderson Cancer Center. The study used multi-platform analyses of tumor samples to discover that ARID1A mutations in tumor cells and expression of the immune signaling protein CXCL13 in surrounding immune cells were enriched in patients who...